Filter Results:
(233)
Show Results For
- All HBS Web
(1,032)
- People (4)
- News (233)
- Research (609)
- Events (7)
- Multimedia (24)
- Faculty Publications (398)
Show Results For
- All HBS Web
(1,032)
- People (4)
- News (233)
- Research (609)
- Events (7)
- Multimedia (24)
- Faculty Publications (398)
Sort by
- 01 Dec 2018
- News
Raising the Barrio
recently been the headquarters of a drug dealer known as “Tarzan.” It was a symbolic gesture, Rodríguez Larreta acknowledges, but an important one. “Our biggest obstacle was the lack of credibility. For years, [residents] have had... View Details
Keywords: April White
- 04 Sep 2019
- News
Accelerating Scientific Discovery
reduce human disease and suffering influences his work as a health care economist and researcher. “I imagine a world where we have treatments, ideally cures, for diseases where right now we have nothing,” he says. “So the big questions that motivate me are, what are... View Details
Keywords: Jennifer Gillespie
- 01 Jan 2008
- News
Jeffrey R. Immelt, MBA 1982
protein biomarkers that have been identified as the precursor to Alzheimer’s disease. “There’s still no cure,” he observes, “but if you know that someone has the early signs of the disease and combine that with some of the new drugs the... View Details
- 01 Sep 2011
- News
Alumni Team Up to Fight Cancer
networking among its alumni community. Bowes, founding partner of US Venture Partners, and Giusti, founder of the Multiple Myeloma Research Foundation (MMRF), discussed the need for innovative, results-oriented biomedical research and View Details
- 01 Dec 2019
- News
The Race Against Resistance
tide. “If we don’t take steps to slow down or stop drug resistance, we will fall back to a time when simple infections killed people. Can you imagine? That’s a bit of a doomsday perspective, but it’s a call to action.” “We are approaching... View Details
Keywords: Lisa Scanlon Mogolov
- 01 Jun 2018
- News
Floor It
case study with the Multiple Myeloma Research Foundation, GNS Healthcare, the Moffitt Cancer Center’s ORIEN program, and biotech firm Foundation Medicine. Rethinking Drug Trials In an adaptive platform trial, different View Details
Keywords: Julia Hanna; illustration by Mengxin Li
- 01 Aug 2001
- News
Class Day and Commencement 2001
process at drug companies. Looking to the future and emphasizing that "there is no success in business that can compensate for failure at home," Clark told the Class of 2001, "You have the capacity to change the world, and you will touch... View Details
- 18 Sep 2014
- News
Room to grow: global expansion in the middle ground
consulting firm Shaldor, documents the specific strategies various companies pursued. As examples, by focusing on a neglected market segment, Netafim became the world leader in drip irrigation technology, while Teva Pharmaceutical created a scalable, acquisition-based... View Details
- 01 Sep 2004
- News
A Market-Based Prescription
change? Congress has already passed a piece of legislation that is tremendously important to the consumer-driven movement. Health savings accounts, established as part of the Medicare prescription drug bill in 2003, will allow the... View Details
- 24 Sep 2020
- News
The Race for a Vaccine
Pisano says. But vaccines don’t really fit the same business model as high-volume therapeutic drugs; they have an even higher bar for safety and effectiveness, because unlike most other drugs they are administered to healthy populations.... View Details
- 01 Sep 2017
- News
Ink: Miami’s Dark Neon Era, the Language of Success, and Getting Psyched Up
and two other amazing, true stories NEW Hotel Scarface by Roben Farzad “There’s so much unresolved about Miami’s cocaine coming-of-age. I found the address where the Cold War crashed into the war on drugs crashed into the cocaine wars... View Details
- 25 Apr 2014
- News
A revolution in healing
Stéphane Bancel (MBA 2000) is president and CEO of Moderna Therapeutics, which is producing a new drug application that could revolutionize the biotech world. It hinges on messenger RNA, or mRNA, the molecules responsible for transporting... View Details
- 02 Apr 2014
- News
Disrupting the Criminal Supply Chain
her dual law and business degrees to fight some of the world's most disturbing criminals. Since 2011, Brochu, 42, has been the United Nations Office on Drugs and Crime's Expert on Child Exploitation and Human Trafficking, a position she... View Details
- 01 Mar 2008
- News
The Last Frontier
state for people with debilitating but nonterminal diseases like his to receive, with a doctor’s assistance, drugs with which they may take their own lives. Explained Gardner, “Why do this? I want to be involved in public life. I was... View Details
- 01 Sep 2008
- News
Mara Aspinall
higher efficacy rate — 80 percent or more. Is 80 percent efficacy unusual for drugs currently on the market? Across all patients and diseases, drug efficacy averages 50 percent, so half the time they bring... View Details
- 20 Aug 2014
- News
With No Time to Lose
into ALS research, and removed some critical barriers to the development of treatments. “Our focus, from the start, was to get drug companies to invest money in ALS,” says Kremer, who was diagnosed with the disease in 2004, just weeks... View Details
Keywords: Margie Kelley
- 24 Apr 2014
- News
Finding a cure so that others may benefit
call. The foundation wanted to invest in for-profit bioscience companies to spur scientists to find a cure for the disease. O’Donnell is credited with almost singlehandedly raising $250 million in support of this venture philanthropy, which led to the development of... View Details
- 01 Dec 2004
- News
Finding a Balance
Do the rules of business change when a company’s product holds the power of life or death over its customers? That’s a question students must consider when discussing “Cipla,” a case about a $325 million Indian pharmaceutical company that manufactures and sells... View Details
- 01 Mar 2010
- News
Noted & Quoted
“Unfortunately, the technology for growing flu viruses to make vaccines is fifty years old — it’s chicken eggs.” — HBS Professor of Management Practice and former Merck CEO Raymond Gilmartin, at a November HBS panel discussion on drug... View Details
- 25 Jun 2020
- News
Covering All Corners
is coordinating with Gilead Sciences, maker of Remdesivir, to distribute and manufacture the antiviral drug treatment for use in 127 countries, including Egypt. It was recently approved for emergency use by the United States, India,... View Details